Australia's largest stock trading and investment forum Australia's #1 stock forum

IMU

1.82%

5.4¢ imugene limited

You were expecting commercialisation when HER-Vaxx wasn't even...

First 13711 Last

Share
Profile

Follow
AlCp

26,927 Posts.

1740

14/05/24

15:49

Post #: 73818726
Share

Originally posted by fourdollars ↑

Can only speak for myself, but given the SP, maybe my view is not unique ...

I called Her-Vaxx a duster quite early in the piece. Although I had divested a significant portion of my holding at that time, I attended the Yuman and Saul road shows and after hearing them speak, decided to keep the rest of my investment.

From my perspective, they were the only remaining credible people associated with IMU.

Axel had been booted.

Leslie makes me cringe when I hear her speak, and I don't understand how she gets away with the "nudge-nudge, wink-wink" comments, year after year with nothing coming to fruition.

Paul. Nuff said.

Monil ...

The rest of the board just perform as Hopper stooges.

So, given the painfully slow - arguably backward - progress toward commercialising anything, the involvement and enthusiasm of Yuman and Saul, were, IMO, the only things going for IMU in the past 18 months.

The other influence is that whenever IMU has gone quite, its always surprised to the downside when it finally announces something - if it announces anything at all. Those three combination HER-Vaxx trials are a case in point.

As much as people would like to believe that Yuman and Saul think Paul and Leslie are the best things since sliced bread, the reality is that their attraction to IMU is simply financial. Its a vehicle for them to progress / test their research, they couldn't care less about who's in charge. So them slinking into the background doesn't bode well IMO.

Perhaps you understand the science better than the vast majority of investors so these things don't concern you. I'm giving the perspective of one who doesn't and so bases investment on (a) the team involved and (b) progress toward commercialisation as I understand it.

Questions for you: Given your obvious scientific understanding and the amount of research you do - did you reach the conclusion that HER-Vaxx was in trouble before IMU confirmed its deprioritisation? Were you concerned that IMU had apparently taken the decision to deprioritise HER-Vaxx (all those non-started or "active, not-recruiting" combination trials) some time before confirming as much? Do you trust that the same isn't happening with CF33 / Oncarlytics? Do you put the SP decline and the fact that IMU has had to do capital raises at ever lowering prices down to market stupidity, or do you think that the personalities and their relative prominence might be contributing?

Expand

You were expecting commercialisation when HER-Vaxx wasn't even close to Ph1 clinical trial completion??? Come-on bruh, you are not clueless investor of biotech start-up stock. I think there's still a big market for HER-Vaxx as not all treatment current or future will work and Chemotherapy is the last treatment so if HER-Vaxx (still need more clinical data) can assist patient to increase the efficacy of Chemotherapy treatment with adding no toxicity then why wouldn't there be a market for this?????

IMU Price at posting: 7.2¢ Sentiment: None Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

PAM

PAM secures high-grade Chilean copper play in strong territory

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

AZL

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

IVZ

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

There are more pages in this discussion • 1,212 more messages in this thread...

First 13711 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.4¢		Change -0.001(1.82%)		Mkt cap ! $396.8M

Open	High	Low	Value	Volume
5.5¢	5.6¢	5.4¢	$443.4K	8.072M

Buyers (Bids)

No.	Vol.	Price($)
27	3056419	5.4¢

Sellers (Offers)

Price($)	Vol.	No.
5.5¢	120000	1

View Market Depth

No.	Vol.	Price($)
27	3056419	0.054
23	3628513	0.053
21	2089051	0.052
21	1993914	0.051
67	4445029	0.050

Price($)	Vol.	No.
0.055	120000	1
0.056	798869	9
0.057	1637593	13
0.058	320000	3
0.059	467000	5

Last trade - 16.10pm 29/07/2024 (20 minute delay)

IMU (ASX) Chart

You were expecting commercialisation when HER-Vaxx wasn't even...

PAM secures high-grade Chilean copper play in strong territory

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

You were expecting commercialisation when HER-Vaxx wasn't even...

Top Stories

PAM secures high-grade Chilean copper play in strong territory

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News